Format

Send to

Choose Destination
See comment in PubMed Commons below
Surg Clin North Am. 2016 Oct;96(5):1141-56. doi: 10.1016/j.suc.2016.06.006.

Systemic Therapy for Advanced Soft Tissue Sarcoma.

Author information

  • 1Department of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD, USA. Electronic address: jsheng7@jhmi.edu.
  • 2Department of Hematology/Oncology, Fox Chase Cancer Center, 333 Cottman Avenue, Philadelphia, PA 19111, USA.

Abstract

Soft tissue sarcomas are rare tumors that present with distant metastasis in up to 10% of patients. Survival has improved significantly because of advancements in histologic classification and improved management approaches. Older agents such as doxorubicin, ifosfamide, gemcitabine, and paclitaxel continue to demonstrate objective response rates from 18% to 25%. Newer agents such as trabectedin, eribulin, aldoxorubicin, and olaratumab have demonstrated improvements in progression-free survival, overall survival, or toxicity profiles. Future studies on treatment of advanced soft tissue sarcoma will continue to concentrate on reducing toxicity, personalization of therapy, and targeting novel pathways.

KEYWORDS:

Advanced soft tissue sarcoma; Chemotherapy; Novel therapies

PMID:
27542647
DOI:
10.1016/j.suc.2016.06.006
[PubMed - in process]

Publication Types

Publication Types

PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science
    Loading ...
    Support Center